BioMarin Pharmaceutical Inc.

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 14/02/2026 am IST			5-day change	1st Jan Change
59.87 ^USD	-0.12%		+2.99%	+0.74%

13/02	BioMarin Pharmaceutical Inc. Announces Closing of Private Offering of Senior Notes	CI
13/02	BridgeBio's oral drug improves growth in children with dwarfism in late-stage study	RE

Sector Update: Health Care

Published on 12/19/2025 at 11:59 pm IST

MT Newswires

Latest news about BioMarin Pharmaceutical Inc.

13/02	BioMarin Pharmaceutical Inc. Announces Closing of Private Offering of Senior Notes	CI
13/02	BridgeBio's oral drug improves growth in children with dwarfism in late-stage study	RE
12/02	BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial	RE
12/02	Pharma companies left out of Trump's drug-pricing deals look for way in	RE
11/02	Pharma companies left out of Trump's drug-pricing deals look for way in	RE
11/02	Biomarin receives Health Canada notice of compliance with conditions for Voxzogo, for achondroplasia	RE
11/02	BioMarin Receives Health Canada Notice of Compliance with Conditions for Vosoritide, for Achondroplasia	CI
26/01	Sector Update: Health Care Stocks Mixed Premarket Monday	MT
26/01	Biomarin Pharmaceutical Inc. Announces $850 Million of Senior Unsecured Notes Due 2034	CI
26/01	BioMarin Pharmaceutical Plans $850 Million Notes Offering, Lines Up $2 Billion Syndicated Loan	MT
26/01	BioMarin announces proposed private offering of senior notes and syndication of new senior secured term loan facility	RE
21/01	When America Starts to Feel Like a Risky Asset
20/01	Canaccord Genuity Upgrades BioMarin Pharmaceutical to Buy From Hold, Adjusts Price Target to $98 From $84	MT
20/01	Greenland, Tariffs, and the Quiet Revolt of the Bond Market
20/01	Analyst recommendations: Intel, Philip Morris, Duolingo, Netflix, SanDisk…

Chart BioMarin Pharmaceutical Inc.

Duration

Period

BMRN: Dynamic Chart

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Employees

3,040

Sector

Pharmaceuticals

Calendar

25/02 - Q4 2025 Earnings Release (Projected)

More about the company